Meteen naar de inhoud


It is our ambition to contribute to global health by the delivery of better adjuvants to increase the success of vaccination campaigns in developed and developing countries. In pre-clinical studies with various types of antigens in large non-rodent species, our most advanced product gave significantly higher humoral responses than benchmark adjuvants after the first and second immunization.

Remarkably, a single injection with LiteVax Adjuvant gave similar and sometimes even higher antibody titers as two immunizations with benchmark adjuvant. So, it is a promising candidate for single-shot vaccines. The single-shot approach offers clear-cut benefits with respect to costs of vaccination (goods, logistics and staffing), time-to-immunity, complexity of vaccination campaigns and non-adherence. In developing countries with poor infrastructure, these are critical success factors of campaigns and better adjuvants play a decisive role. Furthermore, in emergency situations avoiding the need for a booster offers tremendous advantages.

The adjuvant is supplied as a ready-for-use product, which facilitates vaccine R&D and manufacturing. It is cheap, easy to manufacture, stable, filterable and ready-for-use in aqueous formulations. Pilot production has been completed successfully and manufacturing outline has been established. Test material is available for research purposes under a material transfer agreement. Please contact Luuk Hilgers at LUUK.HILGERS@LITEVAX.COM.